文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

早期前列腺癌中度大分割质子与调强放疗毒性汇总分析

A Pooled Toxicity Analysis of Moderately Hypofractionated Proton Beam Therapy and Intensity Modulated Radiation Therapy in Early-Stage Prostate Cancer Patients.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-02-01

该多中心汇总分析纳入1998至2018年7家中心1850例低危或中危前列腺腺癌患者,比较中度大分割质子束治疗(PBT)与调强放疗(IMRT)的晚期毒性。PBT组与IMRT组晚期3级以上泌尿生殖毒性和2级以上胃肠道毒性均无显著差异,两种 modality 毒性发生率均低。

要点

  • 中度大分割PBT与IMRT的晚期GU和GI毒性无显著差异。
  • 多数患者无晚期GU或GI毒性,总体毒性发生率低。
  • 抗凝药物使用是晚期GI毒性的显著预测因素。

核心结论

  • 中度大分割IMRT与PBT治疗早期前列腺癌的晚期GI和GU毒性均低,两种方式间无差异,均安全耐受。

研究设计与样本

  • 多中心汇总分析纳入7家三级转诊中心1998至2018年经活检证实的低危或中危前列腺腺癌患者1850例。
  • 所有患者接受中度大分割放疗,定义为每日分次250至300 cGy、持续4至6周,按IMRT或PBT分层。
  • IMRT组1282例(中位随访80.0个月),PBT组568例(中位随访43.9个月)。
  • 采用逆概率治疗加权计算校正毒性率,校正因素包括种族、NCCN风险组、年龄、治疗前IPSS(仅GU)和抗凝药物使用(仅GI)。

主要发现

  • 多数患者无晚期GU毒性(56.6%,n=1048)或无晚期GI毒性(74.4%,n=1377)。
  • PBT组与IMRT组晚期3级以上GU毒性分别为2.0%与3.9%(OR 0.47;95%CI 0.17-1.28)。
  • PBT组与IMRT组晚期2级以上GI毒性分别为14.6%与4.7%(OR 2.69;95%CI 0.80-9.05)。

临床怎么用

  • 对于低危或中危早期前列腺癌,中度大分割PBT与IMRT均可作为毒性可接受的放疗选择。
  • 临床决策时可结合抗凝药物使用等GI毒性相关因素进行个体化评估。

局限性

  • 两组中位随访时间不一致(IMRT 80.0个月 vs PBT 43.9个月)。
  • 本文为多中心汇总分析,非随机对照设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Data comparing moderately hypofractionated intensity modulated radiation therapy (IMRT) and proton beam therapy (PBT) are lacking. We aim to compare late toxicity profiles of patients with early-stage prostate cancer treated with moderately hypofractionated PBT and IMRT. METHODS AND MATERIALS: This multi-institutional analysis included patients with low- or intermediate-risk biopsy-proven prostate adenocarcinoma from 7 tertiary referral centers treated from 1998 to 2018. All patients were treated with moderately hypofractionated radiation, defined as 250 to 300 cGy per daily fraction given for 4 to 6 weeks, and stratified by use of IMRT or PBT. Primary outcomes were late genitourinary (GU) and gastrointestinal (GI) toxicity. Adjusted toxicity rates were calculated using inverse probability of treatment weighting, accounting for race, National Comprehensive Cancer Network risk group, age, pretreatment International Prostate Symptom Score (GU only), and anticoagulant use (GI only). RESULTS: A total of 1850 patients were included: 1282 IMRT (median follow-up 80.0 months) and 568 PBT (median follow-up 43.9 months). Overall toxicity rates were low, with the majority of patients experiencing no late GU (56.6%, n = 1048) or late GI (74.4%, n = 1377) toxicity. No difference was seen in the rates of late toxicity between the groups, with late grade 3+ GU toxicity of 2.0% versus 3.9% (odds ratio [OR] 0.47; 95% confidence interval 0.17-1.28) and late grade 2+ GI toxicity of 14.6% versus 4.7% (OR 2.69; confidence interval 0.80-9.05) for the PBT and IMRT cohorts, respectively. On multivariable analysis, no factors were significantly predictive of GU toxicity, and only anticoagulant use was significantly predictive of GI toxicity (OR 1.90; P = .008). CONCLUSIONS: In this large, multi-institutional analysis of 1850 patients with early-stage prostate cancer, treatment with moderately hypofractionated IMRT and PBT resulted in low rates of toxicity. No difference was seen in late GI and GU toxicity between the modalities during long-term follow-up. Both treatments are safe and well tolerated.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Vapiwala N, Wong JK, Handorf E, et al. A Pooled Toxicity Analysis of Moderately Hypofractionated Proton Beam Therapy and Intensity Modulated Radiation Therapy in Early-Stage Prostate Cancer Patients. Int J Radiat Oncol Biol Phys. 2021. PMID: 33539968. doi:10.1016/j.ijrobp.2021.01.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。